Advanced search
Publication Cover
Journal of Medical Economics Volume 13, 2010 - Issue 3
Submit an article Journal homepage
507
Views
12
CrossRef citations to date
0
Altmetric
Original Article

Glatiramer acetate and interferon beta-1a for intramuscular administration: a study of outcomes among multiple sclerosis intent-to-treat and persistent-use cohorts

Jane Castelli-Haley Teva Neuroscience, Kansas City, MO, USA
,
MerriKay A. Oleen-Burkey Teva Neuroscience, Kansas City, MO, USA
,
Maureen J. Lage HealthMetrics Outcomes Research, Groton, CT, USACorrespondence[email protected]
&
Kenneth Johnson University of Maryland and Maryland Center for Multiple Sclerosis, Baltimore, MD, USA
Pages 464-471 | Accepted 25 May 2010, Published online: 28 Jul 2010

Citations (12)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (3)

Gorana Capkun, Raquel Lahoz, Elisabetta Verdun, Xue Song, Weston Chen, Jonathan R. Korn, Frank Dahlke, Rita Freitas, Kathy Fraeman, Jason Simeone, Barbara H. Johnson & Beth Nordstrom. (2015) Expanding the use of administrative claims databases in conducting clinical real-world evidence studies in multiple sclerosis. Current Medical Research and Opinion 31:5, pages 1029-1039.
Read now
Gabriel Adelman, Stanley G. Rane & Kathleen F. Villa. (2013) The cost burden of multiple sclerosis in the United States: a systematic review of the literature. Journal of Medical Economics 16:5, pages 639-647.
Read now
M. A. Oleen-Burkey, A. Dor, J. Castelli-Haley & M. J. Lage. (2011) The relationship between alternative medication possession ratio thresholds and outcomes: evidence from the use of glatiramer acetate. Journal of Medical Economics 14:6, pages 739-747.
Read now

Articles from other publishers (9)

Ana Laura M. R. Tomiyama, Luciana Politti Cartarozzi, Lilian de Oliveira Coser, Gabriela Bortolança Chiarotto & Alexandre L. R. Oliveira. (2023) Neuroprotection by upregulation of the major histocompatibility complex class I (MHC I) in SOD1G93A mice. Frontiers in Cellular Neuroscience 17.
Crossref
Maria K. HoutchensNatalie C. EdwardsAmy L. Phillips. (2018) Relapses and disease-modifying drug treatment in pregnancy and live birth in US women with MS. Neurology 91:17.
Crossref
Michael Munsell, Molly Frean, Joseph Menzin & Amy L. Phillips. (2017) Development and validation of a claims-based measure as an indicator for disease status in patients with multiple sclerosis treated with disease-modifying drugs. BMC Neurology 17:1.
Crossref
Tjalf Ziemssen, Jennie Medin, C. Anne-Marie Couto & Catherine R. Mitchell. (2017) Multiple sclerosis in the real world: A systematic review of fingolimod as a case study. Autoimmunity Reviews 16:4, pages 355-376.
Crossref
Guillermo Izquierdo, Nuria García-Agua Soler, Macarena Rus & Antonio José García-Ruiz. (2015) Effectiveness of glatiramer acetate compared to other multiple sclerosis therapies. Brain and Behavior 5:6, pages n/a-n/a.
Crossref
Cathryn A Carroll, Kathleen A Fairman & Maureen J Lage. (2014) Updated cost-of-care estimates for commercially insured patients with multiple sclerosis: retrospective observational analysis of medical and pharmacy claims data. BMC Health Services Research 14:1.
Crossref
Carmen Arnal-García, Maria del Campo Amigo-Jorrin, Ana Maria López-Real, Carme Lema-Devesa, Noemi Llopis & R. Sanchez-de la Rosa. (2014) Long-term effectiveness of glatiramer acetate in clinical practice conditions. Journal of Clinical Neuroscience 21:12, pages 2212-2218.
Crossref
Lesley J. Scott. (2013) Glatiramer Acetate: A Review of Its Use in Patients with Relapsing-Remitting Multiple Sclerosis and in Delaying the Onset of Clinically Definite Multiple Sclerosis. CNS Drugs 27:11, pages 971-988.
Crossref
Oscar Fernández. (2012) Clinical Utility of Glatiramer Acetate in the Management of Relapse Frequency in Multiple Sclerosis. Journal of Central Nervous System Disease 4, pages JCNSD.S8755.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.